Organon & Co. (OGN) fundamentals score
• Women’s Health : Its women’s health portfolio of products is sold by prescription primarily in two therapeutic areas: contraception, with key brands such as Nexplanon (etonogestrel implant) (sold as Implanon NXT in some countries outside the United States) and NuvaRing (etonogestrel / ethinyl estradiol vaginal ring); and fertility, with key brands such as Follistim AQ (follitropin beta injection) (marketed in most countries outside the United States as Puregon ).
Pharmaceutical Preparations · Healthcare · Listed on NYSE
Overall: 5.7 out of 10, Mixed fundamentals
- Growth: 4.0/10
- Profitability: 6.0/10
- Financial health: 5.2/10
- Earnings quality: 8.9/10
- Valuation: 5.7/10
Scores are calculated from Organon & Co.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10